AR093519A1 - 1,6-naftiridinas sustituidas - Google Patents
1,6-naftiridinas sustituidasInfo
- Publication number
- AR093519A1 AR093519A1 ARP130104234A ARP130104234A AR093519A1 AR 093519 A1 AR093519 A1 AR 093519A1 AR P130104234 A ARP130104234 A AR P130104234A AR P130104234 A ARP130104234 A AR P130104234A AR 093519 A1 AR093519 A1 AR 093519A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- optionally substituted
- substituted
- halogen
- alkoxy
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 20
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical group 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- -1 cyano, hydroxy Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 208000009205 Tinnitus Diseases 0.000 abstract 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 231100000886 tinnitus Toxicity 0.000 abstract 2
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 abstract 1
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 abstract 1
- MUGSKSNNEORSJG-UHFFFAOYSA-N 3174-74-1 Chemical group C1CC=CCO1 MUGSKSNNEORSJG-UHFFFAOYSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 102000014461 Ataxins Human genes 0.000 abstract 1
- 108010078286 Ataxins Proteins 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010008025 Cerebellar ataxia Diseases 0.000 abstract 1
- 206010011878 Deafness Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010061323 Optic neuropathy Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 1
- 201000007737 Retinal degeneration Diseases 0.000 abstract 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000010370 hearing loss Effects 0.000 abstract 1
- 231100000888 hearing loss Toxicity 0.000 abstract 1
- 208000016354 hearing loss disease Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 229960001252 methamphetamine Drugs 0.000 abstract 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 abstract 1
- 229940127240 opiate Drugs 0.000 abstract 1
- 208000020911 optic nerve disease Diseases 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 abstract 1
- 229950010883 phencyclidine Drugs 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 230000004258 retinal degeneration Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 230000035882 stress Effects 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente se refiere al uso de compuestos de la fórmula general (1) en la que: R es hidrógeno o alquilo inferior; R¹ es halógeno, alquilo inferior, cicloalquilo o ciano; o es fenilo, opcionalmente sustituido de una a tres veces por sustituyentes elegidos entre alquilo inferior, alquilo inferior sustituido por halógeno, alcoxi inferior, alcoxi inferior sustituido por halógeno, halógeno, ciano, hidroxi, C(O)-NH-alquilo inferior, CH₂-C(O)-NH-alquilo inferior, CH₂-NH-C(O)-alquilo inferior, CH₂NH₂, S(O)₂CH₃, S(O)₂N(CH₃)₂, o por grupos heterocicloalquilo; o es pirazol-1-, -4- ó -5-ilo, opcionalmente sustituido por alquilo inferior; o es tiazol-5-ilo, opcionalmente sustituido por uno o dos grupos alquilo inferior; o es piridin-2-, -3- ó -4-ilo, opcionalmente sustituido por alquilo inferior, alcoxi inferior, halógeno o N(CH₃)₂; o es 3,6-dihidro-2H-pirano; o es benzo[d][1,3]dioxol-5-ilo; o es 2,3-dihidrobenzo[b][1,4]dioxin-6-ilo; R² es hidrógeno, alquilo inferior o alquilo inferior sustituido por alcoxi; R³ es hidrógeno, alquilo inferior, alquilo inferior Sustituido por halógeno, alquilo inferior sustituido por hidroxi, NH-S(O)₂CH₃, -(CH₂)ₘ-O-alquilo inferior o -(CH₂)ₙ-S(O)₂-CH₃; o es -(CR²)ₙ-fenilo, opcionalmente sustituido por -S(O)₂CH₃ o alcoxi inferior; o es -(CH₂)ₙ-heterocicloalquilo opcionalmente sustituido por alquilo inferior y =O; o es -(CH₂)ₙ-heteroarilo opcionalmente sustituido por uno o dos grupos alquilo inferior; o es -(CH₂)ₙ-cicloalquilo opcionalmente sustituido por ciano; o R² y R³ junto con el átomo de N, al que están unidos, forman un anillo heterocíclico elegido entre morfolina, piperidina, 1,1-dioxo-tiomorfolina y piperazina, que puede estar sustituido por alquilo inferior o C(O)O-alquilo inferior, o pueden formar un anillo pirrolidina, opcionalmente sustituido por hidroxi; R es con independencia hidrógeno o alquilo inferior; n es el número 0, 1, 2, 3; m es el número 2; o una sal de adición de ácido farmacéuticamente aceptable, una mezcla racémica o sus enantiómeros correspondientes y/o isómeros ópticos de los mismos, para el tratamiento de la esquizofrenia, el trastorno de personalidad obsesivo-compulsivo, la depresión, los trastornos bipolares, los trastornos de ansiedad, el envejecimiento normal, la epilepsia la degeneración retinal, la lesión cerebral traumática, la lesión de la médula espinal, el trastorno de estrés post-traumático el trastorno de Pánico, la enfermedad de Parkinson la demencia, la enfermedad de Alzheimer el desequilibrio cognitivo moderado, la disfunción cognitiva inducida por la quimioterapia (quimiocerebro), el síndrome de Down, los trastornos del espectro autista, la pérdida de audición, el tintineo (tinnitus, acufenos) la ataxia espinocerebelar, la esclerosis lateral amiotrófica la esclerosis múltiple, la enfermedad de Huntington, la apoplejía, los trastornos debidos a la terapia de radiación el estrés crónico, la neuropatía óptica o degeneración macular, o el abuso de drogas neuroactivas elegidas entre alcohol, opiáceos, metanfetamina, fenciclidina y cocaína.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12193311 | 2012-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR093519A1 true AR093519A1 (es) | 2015-06-10 |
Family
ID=47189816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130104234A AR093519A1 (es) | 2012-11-20 | 2013-11-18 | 1,6-naftiridinas sustituidas |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9657014B2 (es) |
| EP (1) | EP2922540A1 (es) |
| JP (1) | JP2016505534A (es) |
| KR (1) | KR20150085538A (es) |
| CN (1) | CN104812387A (es) |
| AR (1) | AR093519A1 (es) |
| BR (1) | BR112015011094A2 (es) |
| CA (1) | CA2890685A1 (es) |
| HK (1) | HK1207317A1 (es) |
| MX (1) | MX2015006364A (es) |
| RU (1) | RU2015120217A (es) |
| TW (1) | TW201425312A (es) |
| WO (1) | WO2014079787A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI529171B (zh) * | 2013-07-29 | 2016-04-11 | 赫孚孟拉羅股份公司 | １，７－萘啶衍生物 |
| EP3169678A1 (en) * | 2014-07-17 | 2017-05-24 | Merck Patent GmbH | Novel naphthryidines and isoquinolines and their use as cdk8/19 inhibitors |
| KR20170117479A (ko) * | 2015-02-11 | 2017-10-23 | 바실리어 파마슈티카 인터내셔널 리미티드 | 치환된 모노- 및 폴리아자나프탈렌 유도체 및 이의 용도 |
| CN108516958B (zh) | 2015-03-24 | 2020-07-17 | 上海璎黎药业有限公司 | 稠环衍生物、其制备方法、中间体、药物组合物及应用 |
| PE20181010A1 (es) * | 2015-11-06 | 2018-06-26 | Neurocrine Biosciences Inc | Derivados de n-[2-(1-benzilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazina-1-carboxamida y compuestos relacionados como antagonistas del receptor muscarinico 4 (m4) para tratar trastornos neurologicos |
| EA039638B1 (ru) * | 2016-01-06 | 2022-02-21 | Нейрокрин Байосайенсиз, Инк. | Антагонисты мускаринового рецептора 4 и способы их применения |
| EP3591040A4 (en) | 2017-03-03 | 2020-11-11 | Kyoto University | METHOD FOR PRODUCING PANCREATIC ANALYZER CELLS |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9605437D0 (en) | 1996-03-15 | 1996-05-15 | Iaf Biochem Int | Cytomegalovirus inhibiting compounds |
| JP2001525365A (ja) * | 1997-12-11 | 2001-12-11 | バイオケム・フアーマ・インコーポレーテツド | 抗ウイルス化合物 |
| WO2002051413A2 (en) | 2000-12-27 | 2002-07-04 | Shire Biochem Inc. | Macrocyclic anti-viral compounds |
| MX2007001267A (es) * | 2004-08-03 | 2007-07-11 | Serenex Inc | Derivados de naftiridinas 2,8-disustituidas. |
| FR2904317A1 (fr) | 2006-07-27 | 2008-02-01 | Inst Nat Sante Rech Med | Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques |
| US20080242694A1 (en) | 2006-09-18 | 2008-10-02 | D Sidocky Neil R | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith |
| WO2008046072A2 (en) | 2006-10-13 | 2008-04-17 | The Board Of Regents Of The University Of Texas System | Chemical inducers of neurogenesis |
| NZ593996A (en) * | 2009-01-19 | 2012-10-26 | Daiichi Sankyo Co Ltd | Naphthyridine-carboxamide and isoquinoline-carboxamide derivatives for treating osteoporosis |
| WO2010101949A1 (en) * | 2009-03-02 | 2010-09-10 | Sirtris Pharmaceuticals, Inc. | 8-substituted quinolines and related analogs as sirtuin modulators |
| KR20120006016A (ko) | 2009-04-06 | 2012-01-17 | 다이이찌 산쿄 가부시키가이샤 | 치환 페닐기를 갖는 고리형 화합물 |
| JP6126528B2 (ja) | 2010-07-07 | 2017-05-10 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｅｘａｓ Ｓｙｓｔｅｍ | 神経新生促進化合物 |
| JP2012036168A (ja) | 2010-07-15 | 2012-02-23 | Daiichi Sankyo Co Ltd | ヘテロ原子を有する環状化合物を含有する医薬組成物 |
-
2013
- 2013-11-18 CN CN201380060294.0A patent/CN104812387A/zh active Pending
- 2013-11-18 TW TW102141946A patent/TW201425312A/zh unknown
- 2013-11-18 JP JP2015543399A patent/JP2016505534A/ja active Pending
- 2013-11-18 EP EP13795705.6A patent/EP2922540A1/en not_active Withdrawn
- 2013-11-18 RU RU2015120217A patent/RU2015120217A/ru not_active Application Discontinuation
- 2013-11-18 AR ARP130104234A patent/AR093519A1/es unknown
- 2013-11-18 KR KR1020157016208A patent/KR20150085538A/ko not_active Application Discontinuation
- 2013-11-18 WO PCT/EP2013/074012 patent/WO2014079787A1/en active Application Filing
- 2013-11-18 BR BR112015011094A patent/BR112015011094A2/pt not_active IP Right Cessation
- 2013-11-18 MX MX2015006364A patent/MX2015006364A/es unknown
- 2013-11-18 CA CA2890685A patent/CA2890685A1/en not_active Abandoned
-
2015
- 2015-05-20 US US14/717,109 patent/US9657014B2/en not_active Expired - Fee Related
- 2015-08-20 HK HK15108069.2A patent/HK1207317A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015011094A2 (pt) | 2017-07-11 |
| CN104812387A (zh) | 2015-07-29 |
| TW201425312A (zh) | 2014-07-01 |
| US9657014B2 (en) | 2017-05-23 |
| WO2014079787A1 (en) | 2014-05-30 |
| MX2015006364A (es) | 2015-10-05 |
| US20150252044A1 (en) | 2015-09-10 |
| KR20150085538A (ko) | 2015-07-23 |
| JP2016505534A (ja) | 2016-02-25 |
| HK1207317A1 (en) | 2016-01-29 |
| EP2922540A1 (en) | 2015-09-30 |
| RU2015120217A (ru) | 2017-01-10 |
| CA2890685A1 (en) | 2014-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR093519A1 (es) | 1,6-naftiridinas sustituidas | |
| AR097088A1 (es) | Derivados de 1,7-naftiridina | |
| AR096371A1 (es) | 2-fenilimidazo[1,2-a]pirimidinas | |
| AR096640A1 (es) | Derivados de indolin-2-ona o pirrolo-piridin / pirimidin-2-ona | |
| MX2016008842A (es) | Derivados de n-fenil-lactama capaces de estimular la neurogenesis y su uso en el tratamiento de trastornos neurologicos. | |
| MX2015015052A (es) | Derivados de isoquinolina que estimulan la neurogenesis. | |
| AR093576A1 (es) | Derivados heterociclicos sustituidos | |
| AR106588A1 (es) | Derivados de indolin-2-ona para el tratamiento de enfermedades del snc | |
| MX2015017343A (es) | Derivados de pirrolopiridina o pirazolopiridina. | |
| AR080083A1 (es) | Moduladores de gamma-secretasa | |
| AR060647A1 (es) | Derivados de piperidina con actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarinico, composiciones farmaceuticas que los comprenden, el uso de los mismos para la fabricacion de medicamentos para el tratamiento de afecciones pulmonares, metodos para preparar estos der | |
| BR112015004942A2 (pt) | benzimidazóis como agentes ativos do snc | |
| AR106589A1 (es) | Derivados de indolin-2-ona | |
| AR077960A1 (es) | Derivados de benzamida n-sustituidos como inhibidores del transportador de glicina 1 (glyt-1) | |
| PH12016500605A1 (en) | Pyrido[4,3-b]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders | |
| AR073794A1 (es) | Derivados heterociclicos de triazinas sustituidas, medicamentos que los contienen, proceso para prepararlos y uso de los mismos para el tratamiento del alzheimer y otro tipo de demencias. | |
| CO6341621A2 (es) | Piperidinas arilamino y heteroarilamino sustituidas como inhibidores de glyt-1 | |
| AR092041A1 (es) | Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona | |
| BR112015008200A2 (pt) | derivados de imidazopiridina | |
| AR095970A1 (es) | Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona como estimuladores de nsc | |
| AR100532A1 (es) | Derivados de indolín-2-ona y 1,3-dihidro-pirrolo[3,2-c]piridín-2-ona | |
| MX2015000629A (es) | Moduladores de benzisoxasol de neurogenesis. | |
| MX2016001528A (es) | Derivados de indol-carboxamida. | |
| AR081498A1 (es) | Derivados de n-alquil -y n-acil-tetrahidroisoquinolina sustituidos, preparacion y su uso terapeutico de los mismos | |
| TH165816B (th) | ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |